Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) Bundle
As of December 2025, investors are taking notice of Tianjin Ringpu Bio-Technology Co., Ltd. (300119.SZ): with a market capitalization of CNY 8.96 billion and trailing twelve‑month revenue of CNY 3.37 billion, the mid‑cap animal‑health player combines steady topline growth (TTM revenue +0.27% YoY) and operational efficiency (net profit margin of 12.64% in Q3 2025) that appeal to both institutional and retail buyers; strategic backing is significant - Tianjin Huapu Haihe Biopharmaceutical Industry Fund Partnership holds a commanding 35% stake while Ringpu's acquisition of a 56.31% stake in Zhongrui Supply Chain signals expansion into the pet‑health market - all against a low‑volatility profile (beta 0.288) and analyst 12‑month target of CNY 26.15, making the company's ownership mix (including major insider Lei Xu and an employee base of 2,900) and R&D commitment (~12% of revenue in 2022) essential lenses for investors deciding who's buying and why
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Who Invests in Tianjin Ringpu Bio-Technology Co.,Ltd. and Why?
Tianjin Ringpu Bio-Technology Co.,Ltd. has, as of December 2025, attracted a mixed investor base made up of institutional investors, individual shareholders and strategic partners. Key drivers include its position in China's expanding animal and pet health markets, vertical integration across API-to-formulation, recent strategic acquisitions and consistent profitability metrics.- Institutional investors: attracted by market position in animal health, scale advantages and predictable cash flows.
- Individual investors: drawn by steady revenue growth and profitability (net profit margin ~12.64% in Q3 2025).
- Strategic investors/partners: demonstrate long-term commitment and hands-on support for expansion and M&A.
| Investor Type | Representative Stake/Example | Primary Motivation | Relevant Metric/Fact |
|---|---|---|---|
| Strategic investor | Tianjin Huapu Haihe Biopharmaceutical Industry Fund Partnership - 35% | Long-term strategic alignment, board influence, funding for expansion | 35% controlling stake |
| Institutional investors | Mutual funds, asset managers (aggregate holdings; diversified) | Stable returns from animal-health niche, scale and distribution advantages | Targeted for steady cash flow exposure in growing sector |
| Individual (retail) investors | Retail accounts across A-share exchanges | Attracted to revenue growth and reported profitability | Net profit margin ≈ 12.64% (Q3 2025) |
| Strategic/operational investments | Acquisition: 56.31% of Zhongrui Supply Chain | Pet health expansion, supply-chain integration and market extension | 56.31% majority stake in Zhongrui |
- Diversified product mix: APIs, intermediates, finished formulations covering livestock and companion animals.
- Vertical integration: in-house API production through to finished dosage forms improves margins and supply security.
- Pet health expansion: acquisition and dedicated initiatives create new mid/long-term revenue streams.
- Strategic backing: 35% institutional/strategic ownership signals aligned governance and capital support.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) Institutional Ownership and Major Shareholders of Tianjin Ringpu Bio-Technology Co.,Ltd.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) exhibits a concentrated capital structure with clear institutional anchors and meaningful insider stakes that shape governance and strategic direction. Below is a concise profile of the key holders and ownership metrics that investors typically examine.| Holder | Type | Reported Stake | Notes |
|---|---|---|---|
| Tianjin Huapu Haihe Biopharmaceutical Industry Fund Partnership | Institutional (Private equity / industry fund) | 35.0% | Principal institutional backer; largest single shareholder |
| Tianjin Huapu Biopharmaceutical Technology Partnership | Subsidiary of Huapu Haihe (institutional) | ≈1.5% | Related-party institutional holding; complements Huapu Haihe's control |
| Lei Xu | Individual / Insider (General Manager & Director) | Largest individual shareholder (stake not publicly specified) | Significant insider alignment with management |
| Employees (aggregate) | Internal workforce | - | 2,900 total employees; potential for employee share programs (undisclosed) |
| Free float / other institutional & retail investors | Market | Remainder | Residual public float after major holdings |
- Combined Huapu-related ownership (Huapu Haihe + Huapu Biopharm Technology Partnership) ≈ 36.5%, signaling dominant institutional influence.
- Insider ownership led by Lei Xu adds management-aligned governance incentives, though exact percentage is undisclosed.
- Employee base of 2,900 suggests material human-capital scale and potential for equity-linked compensation programs that could affect future share supply.
- Market capitalization: ≈ CNY 8.96 billion (as of Dec 2025).
- Trailing twelve-month revenue: CNY 3.37 billion, supporting mid-cap valuation in pharmaceutical/biotech segments.
- Strategic control: A ~35% stake by a single industry fund provides de facto strategic influence over board composition, M&A appetite, capital allocation, and long-term R&D investment decisions.
- Confidence signal: Large institutional backing often signals due diligence, sector expertise, and willingness to support multi-year development cycles common in biotech.
- Liquidity and activism risk: High concentrated holdings can reduce free float, increasing price volatility on news and giving large holders leverage for operational or governance changes.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) Key Investors and Their Impact on Tianjin Ringpu Bio-Technology Co.,Ltd.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) benefits from a concentrated investor base and strategic ownership that shape capital allocation, governance alignment, and growth direction-particularly toward animal health, vaccines, APIs, and pet-health expansion.- Tianjin Huapu Haihe Biopharmaceutical Industry Fund Partnership - 35.0% stake: provides large-scale financial backing enabling strategic initiatives, M&A capacity, and balance-sheet support.
- Tianjin Huapu Biopharmaceutical Technology Partnership - 1.5% stake: contributes to the capital structure and signals continued institutional support from Huapu-affiliated vehicles.
- Lei Xu - General Manager & Director: management shareholding aligns executive incentives with shareholder value and operational execution.
| Investor / Party | Ownership (%) | Primary Impact |
|---|---|---|
| Tianjin Huapu Haihe Biopharmaceutical Industry Fund Partnership | 35.00 | Major financial backer; facilitates strategic projects, capital allocation, and risk tolerance for expansion. |
| Tianjin Huapu Biopharmaceutical Technology Partnership | 1.50 | Minor institutional stake; enhances credibility and liquidity in the shareholder base. |
| Lei Xu (General Manager & Director) | Substantial (management ownership) | Aligns management and shareholder interests; supports long-term operational discipline. |
| Tianjin Ringpu (acquisition target) - Zhongrui Supply Chain | 56.31 (acquired stake) | Entry and scale-up in the pet health/supply-chain segment; diversifies revenue mix. |
- Strategic M&A: The 56.31% acquisition of Zhongrui Supply Chain positions Tianjin Ringpu to capture higher-margin pet-health channels and cross-sell vaccines/APIs into a growing companion-animal market.
- Product diversification: A balanced portfolio across vaccines and active pharmaceutical ingredients (APIs) reduces single-product risk and opens multiple end-market levers for growth.
- R&D commitment: Approximately 12% of 2022 revenue allocated to R&D underpins product pipeline development, regulatory filings, and long-term competitiveness.
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) Market Impact and Investor Sentiment
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) occupies a meaningful niche in China's pharmaceutical and animal-health markets. Market participants are focusing on a combination of steady top-line growth, healthy margins, strategic M&A in pet health, and low relative volatility when assessing the stock's role in portfolios.
- Market capitalization: ≈ CNY 8.96 billion (Dec 2025).
- Trailing twelve months revenue: CNY 3.37 billion (T12M), +0.27% YoY.
- Q3 2025 net profit margin: ~12.64%.
- Acquisition: 56.31% stake in Zhongrui Supply Chain (strengthens pet health & supply-chain integration).
- Analyst 12-month price target: CNY 26.15 (implies potential upside vs. current trading level).
- Beta: 0.288 (lower volatility vs. market; appeals to risk-averse investors).
| Metric | Value | Comment |
|---|---|---|
| Market Capitalization | CNY 8.96 billion | Reflects mid-cap presence in pharma / animal health |
| Revenue (T12M) | CNY 3.37 billion | Modest YoY growth of 0.27% |
| Net Profit Margin (Q3 2025) | 12.64% | Indicates operational efficiency |
| Key M&A | 56.31% stake in Zhongrui Supply Chain | Enhances pet-health footprint and distribution control |
| Analyst 12M Price Target | CNY 26.15 | Consensus suggests upside potential |
| Beta | 0.288 | Lower volatility; defensive appeal |
Investor sentiment is driven by several structural and tactical forces:
- Strategic buyers and long-only funds: attracted to steady margins and low beta for portfolio diversification.
- Specialized healthcare and animal-health investors: value the Zhongrui acquisition for vertical integration and pet market exposure.
- Event-driven and activist investors: monitor M&A execution and potential value-unlocking moves tied to the new stake.
- Retail investors: follow analyst targets and stability metrics; price target of CNY 26.15 acts as a reference.
Key market-impact vectors to watch:
- Integration of Zhongrui Supply Chain: revenue mix shift toward pet health could lift growth and margins if cross-selling and distribution synergies materialize.
- Profitability resilience: a 12.64% net margin in Q3 2025 underpins confidence in cost control and pricing power.
- Volatility profile: beta of 0.288 supports allocation by risk-averse institutions seeking lower-correlation names in health care.
- Analyst expectations vs. price: the CNY 26.15 12-month target sets upside psychology; relative valuation and earnings trajectory will determine momentum.
For deeper financial context, see related analysis: Breaking Down Tianjin Ringpu Bio-Technology Co.,Ltd. Financial Health: Key Insights for Investors
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.